Stabilisation of T-Cell Activation Markers

Measurement of T-cell activation can be important when assessing immune responses, however cells can become artificially activated over time once removed from the body.

TransFix has been used to stabilise activated T-cell populations. We’ve presented a selection of publications to highlight the versatility of TransFix below. Read on to find out the different ways that researchers benefit from sample stabilisation when studying T-Cell activation.

Measurement of Immune System Activation in HIV-2 Infection.

Almost 10 years ago, Leligdowicz et al. used TransFix to assess the relationship between HIV-2 plasma virus load and immune system activation using HLA-DR and CD38. TransFix was used to preserve T-Cells for between 2-14 days before they were analysed.

  • Leligdowicz et al. Direct Relationship between Virus Load and Systemic Immune Activation in HIV-2 Infection. J Infect Dis 201 (1): 114-122.

Preserving T-Cell Activation Profiles in Coeliac Disease

Since Leligdowicz’s publication, other publications have since been released. In 2014, Olivares et al. identified activated CD45+HLA-DR+ positive T-cells from TransFix-treated blood in relation to coeliac disease. TransFix allowed room-temperature transportation of samples from collection sites to a central testing site in this clinical trial.

  • Olivares et al. (2014) Double Blind, Randomised, Placebo-Controlled Intervention Trial to Evaluate the Effects of Bifido Longum CECT 7347 in Children with Newly Diagnosed Coeliac Disease. British Journal of Nutrition 112 (1); 30-40.

Stabilising T-Cell Activation Profile in Response to Therapeutic Antibodies

Poirier et al. used TransFix to stabilise the immune profile in their clinical trial, using CD69+ and CD25+ to identify activated T-cells in response to anti-CD28 therapy; FR104. TransFix allowed collection of samples from very frequent timepoints (0.5, 0.75, 1, 2, 4, 8 and 24 hours) monitoring the response to the drug, allowing all samples to be analyzed at a more convenient time.

  • Poirier et al. (2016) First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28. J Immunol 197(12): 4593-4602.

For more examples of publications referencing the use of TransFix, visit our bibliography section!

View Bibliography

TransFix Products

TransFix products for sample collection and preservationTransFix® has been validated with a number of specific sample types and optimised with specially designed sample collection tubes:

If you have a problem with sample degradation in your research, contact us to see if TransFix could help.

About the Author